How Far Is Intracardiac Echocardiography (ICE) from Clinical Adoption Amid Its Surge in the Capital Market?
In 2022, intracardiac echocardiography (ICE) companies such as Tingsheng Technology, Saihe Medical, Bingjing Intelligence, and Xinhuan Technology all completed new rounds of financing, sparking a surge of interest in ICE within the capital markets.
Meanwhile, intracardiac echocardiography (ICE) products developed by Chinese companies have gradually entered the stages of animal experiments and clinical trials, and are poised for regulatory approval and market launch. Domestic ICE products have reached a critical juncture.
In addition, global medical device giants Siemens and Philips,GE Healthcare, Johnson & Johnson, Abbott, and Boston Scientific have all established a presence in the intracardiac echocardiography (ICE) market. Among them, Siemens, Johnson & Johnson, and Philips have launched or developed 3D and 4D ICE products. Meanwhile, several innovative domestic companies are also actively positioning themselves in the 4D ICE sector.
In this context, VCBeat has invited leaders from companies specializing in intracardiac echocardiography (ICE) and heads of investment institutions to discuss the current landscape and development trends of the ICE sector.
Zhang Dongyu
Tingsheng Technology | CEO
Tang Yinan
Yuan Yi Capital | Managing Director
Ms. Tang Yinan possesses overWith 10 years of experience in the healthcare industry, Ms. Tang Yinan previously served on the GE Healthcare China team, where she was engaged in R&D, project management, and marketing of medical devices, gaining cross-functional expertise. She holds an MBA from Cheung Kong Graduate School of Business, a Master’s degree in Biomedical Engineering from Cornell University in the United States, and a Bachelor’s degree in Biochemistry from the University of Hong Kong.
Joined Yuan Yi Capital in 2018 and currently serves as Managing Director, focusing primarily on early-stage investments in medical technology, with a particular emphasis on blue-ocean opportunities arising from the implementation of innovative technologies in the healthcare industry. Led projects include Xunshi Technology, Wushuang Medical, Yisheng Intelligence, Xushui Interconnect, Bozhen Biotech, Femtosecond Technology, Yuanyi Biotech, and Bingjing Intelligence.
Liu Fangde
Huxi Yunbaisheng Technology | CEO
Dr. Fangde Liu, CEO of Hangzhou Huxi YunbaishengFounded Yunbaisheng in 2017, dedicated to developing surgical robots tailored for the Chinese market. Over the past three years, it has developed four surgical robot models, with nearly 1,000 clinical application cases. During the pandemic, it created the world’s first nasopharyngeal swab sampling robot. As a representative of China’s technological response to the epidemic, it was specially invited by the State Council to represent China at the China International Fair for Trade in Services (CIFTIS) and the China International Import Expo (CIIE), and received coverage from People’s Daily, Global Times, and overseas media. Its orthopedic surgical robot performed the world’s first computer-assisted hip revision surgery at Peking University Third Hospital, winning China’s highest award in orthopedics. The system’s role in enabling primary care institutions to perform complex surgeries was reported by Guangming Daily.
Prior to founding his startup, Dr. Liu Fangde was a core researcher at the Centre for Surgical Robotics and the Centre for Medical Big Data at Imperial College London. He successively led multiple flagship European projects on surgical robotics and medical big data, including Europe’s largest surgical robotics project.EDEN2020, and Optimise-MS, a post-marketing surveillance program for degenerative neurological disease medications in multiple European countries.
Dr. Liu Fangde is a nationally recognized outstanding talent in the United Kingdom and a Senior Fellow of the Royal Society of Medicine. Academically, he possesses2018 MICCAI Young Scientist Award; 2017 ACM Multimedia Open Source Software Award of the Year; 2016 ROBIO Best Paper in Robotics Award. Dr. Liu Fangde is among the earliest scientists worldwide to apply deep learning to medical image analysis and achieved the world’s first fully autonomous ultrasound-guided interventional robotic system for nerve procedures. His co-authored paper on using deep learning to accelerate MRI acquisition has been cited over 500 times by DAGAN, becoming a focal point of industrial research in high-end MRI.
【About Tingsheng Technology】
Tingsheng Technology was co-founded by senior scientists in the field of ultrasound, cardiologists, and serial entrepreneurs. Headquartered in Nanjing, China, the company has established an international R&D team and operates research and development centers in both China and the United States. Focusing on technological innovations in cardiac electrophysiology using ultrasound, Tingsheng integrates imaging, mapping, and ablation energy delivery to provide more effective treatments for patients with heart diseases, striving to become a globally influential Chinese brand in the medical device industry.
【About Yuan Yi Capital】
Yuan Yi Capital was established inEstablished in 2016, it is an early-stage venture capital fund focused on the digital health technology sector. It targets early-stage companies in medical devices and equipment with core technologies and innovative business models, precision diagnostics, mobile healthcare and services, and health insurance technology firms. Recent investments include Medxinhui (a commercial health insurance technology company), Shukun Technology (AI-based medical imaging), Xunshi Technology (digital dental solutions), Mingyi Zhonghe (focused on primary care), Beideng Medical (a B2B trading platform for medical devices), and Basecare (early cancer screening based on gene sequencing).
[About Huxi Yunbaisheng]
Hangzhou Huxi Yunbaisheng Technology Co., Ltd. was founded by experts in medical big data and surgical robotics from Imperial College LondonFounded on December 22, 2017, the company brings together top talent from the State Key Laboratory of CAD&CG at Zhejiang University, the National Centre for Computer Animation in the UK, and the Robotics Institute of Harbin Institute of Technology. Its current core business focuses on developing robotics and remote digital surgery systems, including surgical robots, surgical planning and navigation software, and big data systems for analyzing real-world clinical effectiveness. Clinical application scenarios cover cardiovascular intervention, neurosurgical intervention, and neurological pharmacotherapy. The company’s primary clients are manufacturers of implantable consumables and medical devices, as well as pharmaceutical companies; both its clients and partners are industry leaders in China and globally.
[About VCBeat]
VCBeat was founded inIn 2014, it was a new-type industrial service organization that leveraged data as its foundation, research as its core, and brand media as its connector to facilitate the precise aggregation of industrial resources and accelerate the growth of industry disruptors. It provided services such as brand communication, research consulting, data monitoring, and resource/project matchmaking to enterprises, government industrial parks, investment institutions, and other entities within the industrial chain.
【About VBInsight Salon】
「"VB Insights Forum"One of VCBeat’s flagship events, it is a face-to-face platform centered on exploring solutions in the healthcare sector, aiming to“Focusing on Practical Issues, Discussing Industry Trends.” The event centers on the current development status of core themes, conducting in-depth discussions, analyses, and exchanges to address encountered difficulties, pain points, and obstacles. Meanwhile, it seeks to gain a deeper understanding of the resource endowments of enterprises, fostering practical collaborations through the exchange of ideas.